While AI as a diagnostic tool is still years away from regular clinical use, recent research is an important step.
Posts by the Author
Most of last week’s healthcare-related actions involved telemedicine in some way, with the lone lab-related case centering on genetic testing.
While labs were absent from recent enforcement actions, last week saw kickback schemes involving DME companies and a medical device company.
Key Dx announcements last week involved companion diagnostics, liquid biopsy assays, and an RUO leukemia test.
In last week’s key cases, those involved in UDT fraud schemes face the music, and a doctor is convicted of stealing COVID relief money.
The recent Declaration of North America makes updating the current North American Plan for Animal and Pandemic Influenza a priority.
While most recent cases were the usual FCA and kickback-related issues, one involved the mischarging of federal grants by two biotech companies and their co-founder.
DNA sequencing technologies may revolutionize the early detection and prevention of the disease.
Though the federal spending bill passed at the end of December offers another year’s reprieve from PAMA price cuts, SALSA was not included.
In our latest roundup, schemes involving cancer genetic testing and kickbacks remain the most common, but there were some surprises.